Hyloris Raises €80m For Business Development

Company Anticipates First European Approval

 
• By Akriti Seth
  
Generate a summary of this article
Listen to this article
Beta

With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.

Speech_Bubble_Funding
After launching its initial public offering, the Belgian value-added medicine specialist successfully raises €80m through public listing. • Source: Shutterstock

Hyloris Pharmaceuticals SA, a value-added medicines specialist, has successfully raised €80m ($94.6m) through a public listing for the “development of the existing product portfolio, the establishment of infrastructure in the US for the commercialization of the IV cardiovascular portfolio and further expansion of the pipeline, both internally and through business development opportunities.”

Stijn Van Rompay, CEO of Hyloris, commented: “Having successfully completed our public listing on Euronext Brussels, we are well positioned...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

Type:DisclosureDevelopments | Publication:GB | Section:Business | Paywall:Free — Article containing all Composer content for testing (Do not update)

 
• By Nabil and Olga Zviezdicheva

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

ADHD

This is regarding ADHD.

GB-Business-Free-DisclosureDevelopments-The Secret to Walking More: It’s Not Counting Steps

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.